Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Gilead Sciences
Deal Size : $1,700.0 million
Deal Type : Partnership
Gilead, LEO Pharma Partner to Develop Programs for Inflammatory Diseases
Details : The partnership aims to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 programs for the potential treatment of patients with inflammatory diseases.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $250.0 million
January 11, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Gilead Sciences
Deal Size : $1,700.0 million
Deal Type : Partnership
Lead Product(s) : ISD017
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Biogen
Deal Size : Undisclosed
Deal Type : Collaboration
Details : ISD and Biogen will work together to develop ISD's lead compound, ISD 017, which is being developed to treat severe lupus - systemic lupus erythematosus (SLE).
Product Name : ISD017
Product Type : Peptide
Upfront Cash : Undisclosed
November 23, 2020
Lead Product(s) : ISD017
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Biogen
Deal Size : Undisclosed
Deal Type : Collaboration